Jeil Pharmaceutical's Dual SGLT-1/2 Inhibitor JP-2266 Shows Significant HbA1c Reduction in Phase 2 Diabetes Trial
核心洞察
JP-2266, a novel oral SGLT-1 (搜索)/2 dual inhibitor, reduced HbA1c by 0.94% (5 mg) and 0.97% (10 mg) versus placebo in a 12-week Phase 2 trial published in Diabetes and Metabolism Journal.
The proportion of patients achieving HbA1c below 7.0% reached 70.6% in the 10 mg group and 66.7% in the 5 mg group, with significant reductions in both fasting and postprandial glucose.
JP-2266's dual mechanism—combining renal SGLT-2 (搜索) inhibition with intestinal SGLT-1 (搜索) inhibition—differentiates it from existing SGLT-2 inhibitors by targeting post-meal glucose spikes.
Jeil Pharmaceutical (搜索)'s investigational oral type 2 diabetes (搜索) drug JP-2266 has demonstrated clinically meaningful reductions in glycated hemoglobin (HbA1c), fasting blood glucose, and postprandial glucose in a Phase 2 clinical trial, with results now published in the international journal Diabetes and Metabolism Journal (DMJ), which holds an impact factor of 8.2.
JP-2266 is a first-in-concept dual SGLT-1 (搜索)/2 inhibitor that simultaneously blocks glucose reabsorption in the kidneys via SGLT-2 (搜索) inhibition and delays glucose absorption in the small intestine via SGLT-1 inhibition. This dual mechanism distinguishes it from currently marketed SGLT-2 inhibitors, which act solely on the kidney.
Trial Design and Patient Population
The randomized, double-blind, placebo-controlled, multicenter Phase 2 study was conducted at 28 medical institutions across Korea from December 2023 to December 2024, enrolling 156 patients with type 2 diabetes (搜索) whose blood glucose was inadequately controlled through diet and exercise alone. Eligible participants had baseline HbA1c levels between 7.0% and 10.0%. Patients were randomized to receive JP-2266 5 mg, JP-2266 10 mg, or placebo over a 12-week treatment period. The trial was coordinated by Professor Bong Soo Cha of the Department of Endocrinology at Yonsei University College of Medicine, Severance Hospital.
Efficacy Results
At week 12, JP-2266 produced statistically significant reductions in HbA1c compared with placebo. The estimated treatment difference was −0.94% for the 5 mg group and −0.97% for the 10 mg group (P<0.0001 for both doses). The proportion of patients achieving the standard diabetes treatment target of HbA1c below 7.0% was 66.7% in the 5 mg group and 70.6% in the 10 mg group.
Fasting blood glucose also decreased significantly in both JP-2266 groups compared with placebo (P<0.0001 for both). Notably, postprandial glucose levels at both one hour and two hours after meals declined significantly. The reduction in two-hour postprandial glucose at week 12 was approximately 63 to 68 mg/dL across both dose groups (P<0.0001 for both).
Beyond glycemic control, JP-2266 demonstrated additional metabolic benefits. Weight loss was observed in the study population, which had a mean body mass index of 26.0. Systolic blood pressure decreased in the 10 mg treatment group. Improvements were also noted in indicators reflecting insulin resistance and beta-cell function.
Safety Profile
Both doses of JP-2266 were generally well tolerated, with adverse event rates comparable to the placebo group. Most adverse events were mild or moderate in intensity, and all cases resolved during the follow-up period.
Differentiation and Clinical Implications
Professor Cha emphasized the mechanistic distinction of JP-2266: "The effect of lowering postprandial glucose by slowing intestinal glucose absorption through SGLT-1 (搜索) inhibition is a mechanistic feature that distinguishes JP-2266 from conventional SGLT-2 (搜索) inhibitors." He further noted, "By alleviating postprandial glucose peaks, it is expected to reduce the acute workload on the pancreas for insulin secretion and help mitigate beta-cell overload."
Professor Cha also highlighted the relevance of JP-2266's profile for Asian populations: "Given the heightened importance of postprandial glucose management in Asian countries with high carbohydrate consumption, the mechanistic characteristics of JP-2266 may offer clinically meaningful treatment options."
Limitations and Next Steps
As these results derive from a 12-week Phase 2 study, long-term efficacy and safety must be further confirmed in Phase 3 trials. Professor Cha cautioned, "Since these results are based on a Phase 2 clinical trial, further Phase 3 studies are necessary for additional verification of its efficacy and safety."